17:24 , Mar 23, 2018 |  BC Week In Review  |  Clinical News

Inovio reports interim Phase I data for HBV candidate

Inovio Pharmaceuticals Inc. (NASDAQ:INO) reported interim data from a Phase I trial showing that HBV candidate INO-1800 was well tolerated and generated virus-specific T cells, including CD8+ killer T cells. The open-label, dose-escalation, international trial...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Company News

Inovio, Roche deal

Inovio said Roche is terminating a 2013 deal and returning exclusive, worldwide rights to Inovio’s INO-1800 . Roche said the termination was a “strategic decision” and that the pharma will pay Inovio R&D costs per...
07:00 , Aug 3, 2016 |  BC Extra  |  Company News

Roche returning rights to Inovio's HBV vaccine

Inovio Pharmaceuticals Inc. (NASDAQ:INO) said Roche (SIX:ROG; OTCQX:RHHBY) is terminating a 2013 deal and is returning exclusive, worldwide rights to Inovio's hepatitis B vaccine INO-1800 . Inovio expects data in 2H17 from an open-label Phase...
07:00 , May 25, 2015 |  BC Week In Review  |  Clinical News

SynCon DNA HBV vaccine: Phase I started

Inovio began an open-label, dose-escalation, international Phase I trial evaluating INO-1800 alone or in combination with INO-9112, an IL-12-based immune activator, delivered by electroporation in 126 patients. The start triggered a $3 million milestone payment...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

Inovio, Roche deal

Inovio granted Roche exclusive, worldwide rights to prostate cancer vaccine INO-5150 and hepatitis B vaccine INO-1800 , as well as use of Inovio's Cellectra electroporation technology to deliver the vaccines. Roche also has an option...
00:54 , Sep 11, 2013 |  BC Extra  |  Company News

Inovio licenses preclinical immunotherapy vaccines to Roche

Inovio Pharmaceuticals Inc. (NYSE-M:INO) granted Roche (SIX:ROG; OTCQX:RHHBY) exclusive, worldwide rights to prostate cancer vaccine INO-5150 and hepatitis B vaccine INO-1800, as well as use of Inovio's Cellectra electroporation technology to deliver the vaccines. Roche...
08:00 , Dec 17, 2012 |  BC Week In Review  |  Clinical News

Inovio preclinical data

In mice, Inovio's SynCon DNA HBV vaccine delivered with the company's electroporation system induced "strong" antigen-specific T cell and high titer antibody responses systemically and in the liver. Inovio said the T cells cleared HBV...